The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
Abstract
Purpose: This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m 2 as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced soft tissue sarcoma. Patients and Methods: Patients with documented progressive advanced soft tissue sarcoma received ET-743 as second- or third-line chemotherapy. Antitumor activity was evaluated every 6 weeks until progression, excessive toxicity, or patient refusal. Results: One hundred four patients from eight European institutions were included in the study (March 1999 to November 2000). A total of 410 cycles were administered in 99 assessable patients. Toxicity mainly involved reversible grade 3 to 4 asymptomatic elevation of transaminases in 40% of patients, and grade 3 to 4 neutropenia was observed in 52% of patients. There were eight partial responses (PR; objective regression rate, 8%), 45 no change (NC; > 6 months in 26% of patients), and 39 progressive disease. A progression arrest rate (PR + NC) of 56% was observed in leiomyosarcoma and 61% in synovialosarcoma. The median duration of the time to progression was 105 days, and the 6-month progression-free survival was 29%. The median duration of survival was 9.2 months. Conclusion: ET-743 seems to be a promising active agent in advanced soft tissue sarcoma, with no cumulative toxicities. The 6-months progression-free survival observed in advanced soft tissue sarcoma compares favorably with those obtained with other active drugs tested in second-line chemotherapy in previous European Organisation for the Research and Treatment of Cancer trials. The median overall survival was unusually long in these heavily pretreated patients mainly due to the high number of patients who benefit from the drug in terms of tumor control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationGemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Soft tissue sarcomas of adults: state of the translational science.
Borden, E. C., Baker, L. H., Bell, R. S., Bramwell, V. H. C., Demetri, G. D., Eisenberg, B. L., Fletcher, C. D. �., Fletcher, J. A., Ladanyi, M., Meltzer, P. S., et al. (2003) · PubMed · Cited by 612
Self-citationVan Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Self-citationProgression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Self-citationJudson, I., Radford, J. A., Harris, M., Blay, J.-Y., van Hoesel, Q., le Cesne, A., van Oosterom, A. T., Clemons, M. J., Kamby, C., Hermans, C., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00050-8 · Cited by 392
Self-citationSynovial sarcoma. Uniform response of metastases to high dose ifosfamide
Rosen, G., Forscher, C., Lowenbraun, S., Eilber, F., Eckardt, J., Holmes, C., & Fu, Y. S. (1994) · Cancer · doi:10.1002/1097-0142(19940515)73:10<2506::aid-cncr2820731009>3.0.co;2-s · Cited by 273
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., & D'Incalci, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00357-9 · Cited by 262
Le Cesne, A., Judson, I., Crowther, D., Rodenhuis, S., Keizer, H. J., Van Hoesel, Q., Blay, J. Y., Frisch, J., Van Glabbeke, M., Hermans, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2676 · Cited by 256
Self-citationEcteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail-Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 214
Le Cesne, A., Antoine, E., Spielmann, M., Le Chevalier, T., Brain, E., Toussaint, C., Janin, N., Kayitalire, L., Fontaine, F., & Genin, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1600 · Cited by 207
Self-citationBlay, J.-Y., van Glabbeke, M., Verweij, J., van Oosterom, A. T., Le Cesne, A., Oosterhuis, J. W., Judson, I., & Nielsen, O. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00480-x · Cited by 184
Self-citationVerweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., Seynaeve, C., di Paola, E. D., van Glabbeke, M., Tonelli, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2081 · Cited by 171
Self-citationDelaloge, S., Yovine, A., Taamma, A., Riofrio, M., Brain, E., Raymond, E., Cottu, P., Goldwasser, F., Jimeno, J., Misset, J. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1248 · Cited by 168
Self-citationvan Oosterom, A. T., Mouridsen, H. T., Nielsen, O. S., Dombernowsky, P., Krzemieniecki, K., Judson, I., Svancarova, L., Spooner, D., Hermans, C., Van Glabbeke, M., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00491-4 · Cited by 164
Self-citationTaamma, A., Misset, J. L., Riofrio, M., Guzmán, C., Brain, E. G. C., Lázaro, L. L., Rosing, H., Jimeno, J. M., & Cvitkovic, E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1256 · Cited by 161
Self-citationIzbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137
Self-citationRyan, D. P., Supko, J. G., Eder, J. P., Seiden, M. V., Demetri, G. D., Lynch, T. J., Fischman, A. J., Davis, J., Jimeno, J. A., & Clark, J. W. (2001) · PubMed · Cited by 115
Self-citationGemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study
Merimsky, O., Meller, I., Flusser, G., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050027 · Cited by 109
Nielsen, O. S., Dombernowsky, P., Mouridsen, H. T., Crowther, D., Verweij, J., Buesa, J., Steward, W. P., Daugaard, S., Glabbeke, M. M. V., Kirkpatrick, A., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.735 · Cited by 105
Self-citationJimeno, J. M., Faircloth, G. T., Cameron, L., Meely, K., Vega, E., Gómez, A., Sousa-Faro, J. M. F., & RINEHART, K. L. J. (1996) · Drugs of the Future · doi:10.1358/dof.1996.021.11.385487 · Cited by 87
Self-citationTwelves, C. J., Hoekman, K., Bowman, A., Vermorken, J. B., Anthoney, A., Smyth, J., van Kesteren, C., Beijnen, J. H., Uiters, J., Wanders, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00458-1 · Cited by 84
Self-citationVillalona-Calero, M. A., Eckhardt, S. G., Weiss, G. R., Hidalgo, M. M., Beijnen, J. H., van Kesteren, C., Rosing, H., Campbell, E., Kraynak, M. A., Lázaro, L. L., et al. (2002) · PubMed · Cited by 82
Self-citationDifferential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells
Gajate, C., An, F., & Mollinedo, F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204644200 · Cited by 79
Guan, Y., Sakai, R., Rinehart, K. L., & Wang, A. H. ‐. (1993) · PubMed · Cited by 71
Kanzaki, A., Takebayashi, Y., Ren, X. Q., Miyashita, H., Mori, S., Akiyama, S. I., & Pommier, Y. G. (2002) · PubMed · Cited by 69
Metastatic Soft Tissue Sarcoma in Adults
Nielsen, O. S., Blay, J., Judson, I. R., Glabbeke, M. M. V., Verweij, J., & van Oosterom, A. T. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302030-00005 · Cited by 20
Self-citation
Cited by
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0035 · Cited by 1,182
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4734 · Cited by 841
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Metadata
- Authors
- Le Cesne, A., Blay, J. Y., Judson, I., Van Oosterom, A., Verweij, J., Radford, J., Lorigan, P., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., Collin, F., Jimeno, J., Di Paola, E., Van Glabbeke, M., & Nielsen, O. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-01-20
- Volume
- 23
- Issue
- 3
- Pages
- 576-584
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107078868
- Cited by
- 421
- References
- 29
- FWCI
- 17.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.